Thomas C. Tsai, MD, MPH, senior author, metabolic bariatric surgeon, Department of Surgery at Brigham and Women's Hospital Using a national sample of medical insurance claims data from over 17 ...

The researchers found a 25.6% drop in people undergoing bariatric surgery in the final six months of 2023 compared with the number of surgeries people had during the same period the year before.

Tsai, MD, MPH, a metabolic bariatric surgeon in the Department of Surgery at Brigham and Women's Hospital. Using a national sample of medical insurance claims data from over 17 million privately ...

Tsai, MD, MPH, a metabolic bariatric surgeon in the Department of Surgery at Brigham and Women's Hospital. Using a national sample of medical insurance claims data from more than 17 million ...

It found that between 2022 and 2023, as prescriptions for GLP-1 drugs more than doubled, rates of bariatric surgery fell by 25.6%. The findings, published Wednesday in JAMA Network Open ...

"While there have been advances in the first-line treatment of locally advanced unresectable and metastatic gastric and GEJ cancers in the last several years, there is still a tremendous unmet ...

VYLOY is used in conjunction with chemotherapy for the treatment of advanced gastric and gastroesophageal junction cancer. Credit: Emily frost/Shutterstock.com. Astellas Pharma has gained approval ...